Talesnik E, Vial P A, Labarca J, Méndez C, Soza X
Department of Pediatrics, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago. reumatomed.puc.cl.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):471-7. doi: 10.1097/00042560-199812150-00005.
The temporal course of the humoral immune response to T-cell-dependent and T-cell-independent type 2 antigens was evaluated in HIV-infected patients. In all, 26 seropositive patients were vaccinated with tetanus toxoid and 23-valent pneumococcal vaccines; total IgG and IgG1 antibodies to tetanus toxoid (Ttox) and total IgG and IgG2 antibodies against 23 Streptococcus pneumoniae capsular antigens (PPS) were measured at baseline, 2 months, and 12 months after vaccination. For the Ttox, baseline levels of IgG1 (Ttox-IgG1) increased from 11.0 to 19.5 mg/L at 2 months postimmunization. Overall only 6 patients (23%) showed a significant response. At 12 months postvaccination, Ttox-IgG and T-tox-IgG1 were significantly lower than baseline levels (Ttox IgG basal; 11.0 mg/L, 12 months; 0.8 mg/L, Ttox IgG1 baseline; 13.1 mg/L, Ttox IgG1 12 months; 2.4 mg/L) and in 10 patients, antibodies that fell below protective levels (0.6 mg/L). In contrast with PPS, a significant response was observed at 2 and 12 months (PPS-IgG basal; 35.9 U/ml, 2 months; 151.4 U/ml, 12 months; 59.7 U/ml; PPS-IgG2 baseline 20.3 U/ml, 2 months; 113.2 U/ml, 12 months; 51.9 U/ml). Overall, 19 patients (76%) showed an immune response to pneumococcal polysaccharides antigens. Immunization with the Ttox T-cell-dependent antigen fails to elicit a significant immune response and may induce inhibition of antibody production in HIV-infected patients. In contrast, immunization with a T-cell-independent type 2 antigen can cause the pneumococcal polysaccharides to induce significant immune response in a high proportion of HIV-infected patients.
在HIV感染患者中评估了对T细胞依赖性和T细胞非依赖性2型抗原的体液免疫反应的时间进程。总共26名血清反应阳性患者接种了破伤风类毒素和23价肺炎球菌疫苗；在接种疫苗后的基线、2个月和12个月时，检测了针对破伤风类毒素（Ttox）的总IgG和IgG1抗体以及针对23种肺炎链球菌荚膜抗原（PPS）的总IgG和IgG2抗体。对于Ttox，免疫后2个月时IgG1的基线水平从11.0毫克/升增加到19.5毫克/升。总体而言，只有6名患者（23%）显示出显著反应。接种疫苗12个月后，Ttox-IgG和T-tox-IgG1显著低于基线水平（Ttox IgG基线；11.0毫克/升，12个月时；0.8毫克/升，Ttox IgG1基线；13.1毫克/升，Ttox IgG1 12个月时；2.4毫克/升），并且在10名患者中，抗体水平降至保护水平（0.6毫克/升）以下。与PPS相反，在2个月和12个月时观察到显著反应（PPS-IgG基线；35.9 U/ml，2个月时；151.4 U/ml，12个月时；59.7 U/ml；PPS-IgG2基线20.3 U/ml，2个月时；113.2 U/ml，12个月时；51.9 U/ml）。总体而言，19名患者（76%）显示出对肺炎球菌多糖抗原的免疫反应。用Ttox这种T细胞依赖性抗原进行免疫未能引发显著的免疫反应，并且可能在HIV感染患者中诱导抗体产生的抑制。相比之下，用T细胞非依赖性2型抗原进行免疫可使肺炎球菌多糖在很大比例的HIV感染患者中诱导显著的免疫反应。
